Humanized Mice Lead to Breakthroughs in Blood Cancers
Humanized mice created at Yale are opening new avenues of research into cancers caused by disorders in the production of blood, such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Until recently, such research was hindered because human blood stem cells are difficult to grow in cell cultures or to engraft in mice.
Mustaches may lower risk of skin cancer-associated lesions on lips
Having a mustache might lower a person’s risk of developing a specific kind of pre-cancerous lesion on the lower lip known as actinic keratosis, according to a new study published in the Journal of the American Academy of Dermatology.Source: ABC News
Lung Cancer Research Foundation Announces New Scientific Advisory Board Chair
NEW YORK, May 23, 2019 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced that Dr. Katerina Politi has been named the chair of its Scientific Advisory Board. Politi, an Associate Professor of Pathology and Internal Medicine (in the Section of Medical Oncology) at Yale School of Medicine, will be taking over the role from Dr. James B. Dougherty, who has held the chair position for 14 years.Source: Yahoo! Finance
Yale Cancer Center Scientists Receive Grant to Advance Lung Cancer Research
Katerina Politi, PhD and Don Nguyen, PhD, members of the Signal Transduction Research Program at Yale Cancer Center (YCC), have received a 5-year, nearly $4 million National Cancer Institute (NCI) grant to support Lung Cancer research.
Yale Cancer Center Scientists Advise Caution in Immunotherapy Research
In a new study, Yale Cancer Center scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.
Knowing the Risks: The Genetics of Breast and Ovarian Cancer
Dr. Ryan Jensen’s work, spurred by a pair of WHRY grants, continues progress toward models uncovering how genetic mutations lead to cancer and helping guide patients and doctors toward decisions that can produce the best health outcomes.
Yale Cancer Researchers Suggest New Treatment for Rare Inherited Cancer
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests a promising strategy for treatment with drugs recently approved for other forms of cancer.
Gift supports work on a stubborn cancer
Ginny Grunley became a patient of Roy S. Herbst, MD, PhD, after being diagnosed with a form of lung cancer associated with the EGFR gene mutation, also known as non-smoker’s lung cancer. Grunley and her husband Ken have given a million-dollar gift to support Herbst’s research.Source: Medicine@Yale
Clinical trials take innovative approach
Since their arrivals at Yale within the past six years, Joseph Paul Eder, MD, and Patricia LoRusso, DO, have overseen a sharp increase in the number of clinical trials conducted by the Phase I Program at Yale Cancer Center. Bench investigators and the clinicians who design and conduct early-phase trials interact regularly, each sharing knowledge with the other that both strengthens the basic science and brings new discoveries to patients more quickly and effectively.
Researchers develop novel immunotherapy to target colorectal cancer
A Yale-led research team has developed an antibody that blocks tumors in animal models of colorectal cancer. If the finding is confirmed in clinical trials, the antibody-based treatment could become an effective weapon against colorectal cancer, and possibly other cancers, that resist current immunotherapies, the researchers said.